Adma Biologics Inc Recommendation mean
What is the Recommendation mean of Adma Biologics Inc?
The Recommendation mean of Adma Biologics Inc is 1.33
What is the definition of Recommendation mean?
Recommendation mean is the mean of analysts’ ratings of the stock ranging from 1.0 (strong buy) to 5.0 (strong sell).
Mean of recommendations is an average of ratings from different analysts but it should still be used with other research and investment metrics in order to make investment decisions. It is important to understand a firm's entire scale when assimilating ratings. Additionally, analyst recommendations on stocks owned by firms employing them may be seen as potentially biased.
Financial analysts are often employed by mutual and pension funds, hedge funds, securities firms, banks, investment banks, insurance companies, and other businesses, helping these companies or their clients make investment decisions. Financial analysts employed in commercial lending perform "balance sheet analysis," examining the audited financial statements and corollary data in order to assess lending risks. In a stock brokerage house or in an investment bank, they read company financial statements and analyze commodity prices, sales, costs, expenses, and tax rates in order to determine a company's value and project future earnings. In any of these various institutions, the analyst often meets with company officials to gain a better insight into a company's prospects and to determine the company's managerial effectiveness.
Usually, financial analysts study an entire industry, assessing current trends in business practices, products, and industry competition. They must keep abreast of new regulations or policies that may affect the industry, as well as monitor the economy to determine its effect on earnings.
Recommendation mean of companies in the Health Care sector on NASDAQ compared to Adma Biologics Inc
What does Adma Biologics Inc do?
adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.
Companies with recommendation mean similar to Adma Biologics Inc
- NMI Inc has Recommendation mean of 1.31
- Cigna has Recommendation mean of 1.31
- Intercontinental Exchange Inc has Recommendation mean of 1.32
- Boston Scientific has Recommendation mean of 1.32
- Equinix Inc has Recommendation mean of 1.32
- Dynatrace Inc has Recommendation mean of 1.32
- Adma Biologics Inc has Recommendation mean of 1.33
- HDFC Bank has Recommendation mean of 1.34
- Alphabet Inc has Recommendation mean of 1.34
- Angi Inc has Recommendation mean of 1.35
- General Motors has Recommendation mean of 1.35
- Danaher has Recommendation mean of 1.35
- Blackrock has Recommendation mean of 1.35